Do you want to read an article? Please log in or register.
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
Skin Cancer
Related content
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Further Publications
Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely
healthbook TIMES Oncology Hematology
1Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), CH-1011, Switzerland
2International Cancer Prevention Institute, Epalinges, CH-1066, Switzerland
*corresponding authors
Skin Cancer
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Melanoma Res.
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV
doi: 10.1097/CMR.0000000000000654.
SPECIAL REPORT
Further Publications
Adjuvant Targeted Therapy in BRAF-Mutated Melanoma
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
Further Publications
Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
1Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
*equal contribution
SPECIAL REPORT
Multiple Myeloma (MM)
Therapie des rezidivierten/refraktären Multiplen Myeloms
Gastrointestinal CancerFurther Publications
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
healthbook TIMES Oncology Hematology
Corresponding author:
Dr Alexander Siebenhüner
Senior Consultant in Medical Oncology
Cantonal Hospital Schaffhausen
Schaffhausen, Switzerland
RECOMMENDED
Skin Cancer
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol.
Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM,
Long GV
doi: 10.1016/S1470-2045(18)30940-9.